From The Editor

1. A Biotech Business Model That's Investor-Friendly 3/2/2026

   For biotechs meeting with current and potential investors, says Edward Ahn, CEO, Medipost Inc., “it should be about demonstrating your business continuity more than anything else.” Investors know, he says, “any supply chain may be fragile.” Indeed, Ahn’s organization has put in place an intriguing business model to address such concerns. It includes owning part of a CDMO.

2. Taking The First Steps Towards Digitalizing Biopharma Development 1/28/2026

   AbbVie's head of biologics purification development and digitization teams, Moiz Diwan, Ph.D., and independent technology consultant Kat Kozyrytska share their thoughts on AI and smart technology adoption in this recap of the Bioprocess Online Live event, “How Digital Tools Are Accelerating Biopharma Development.” 

3. Bioprocess Online's 2025 Editorial Reflections 12/23/2025

   Bioprocess Online's chief editor, Tyler Menichiello, reflects on the year and provides a preview of what to expect in 2026.

4. We're A Virtual Biotech. CDMOs Should Treat Us As A Priority 11/3/2025

   Chief Editor Louis Garguilo says he's sure some readers will smirk at our headline. CDMOs are running a business; they may attempt to treat all customers equally, but they focus where the most financial gain is. That's usually with bigger clients. Nonetheless, according to a very experienced outsourcing professional, there's nothing humorous here at all.

5. FDA Releases Draft Guidance To Accelerate Biosimilar Development 10/31/2025

   New FDA draft guidance aims to reduce the timeline and cost of developing biosimilars.

6. Supporting The Next Generation Of ADCs 10/30/2025

   Experts discuss innovation in antibody-drug conjugate (ADC) technology and how these impact CMC strategy. This summary captures key takeaways from the Bioprocess Online Live event "Evolving CMC Strategies To Enable Next-Gen ADCs."

7. The 9 Fastest-Growing Outsourcing Segments 10/21/2025

   Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.

8. AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing 10/10/2025

   At BioProcess International 2025, leaders from AbbVie and Amgen gave keynote presentations about how their companies are advancing product development through digital tools.

9. On The Ground At BPI: Kat Kozyrytska On Ethical AI And Collaboration 9/29/2025

   AI consultant Kat Kozyrytska advocates for ethical AI adoption and explains its potential to foster collaboration across the industry.

10. On The Ground At BPI: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing 9/26/2025

    Takeda head of process development, Amy Shaw, explains what factors to consider when scaling up or scaling out cell therapy manufacturing.